Hovione launches new website for the Chinese Market
Hovione is closer to its customers with a new website in Mandarin
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Hovione is closer to its customers with a new website in Mandarin
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Hovione has once again solidified its position as a top employer.
Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®
High Performance, High-Dose Capsule DPI.
Executiva, 23 February 2026
Expand the established chemistry space with Continuous Flow to deliver robust and sustainable processes.